Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00314782 · ClinicalTrials.gov registry record · Phase 1
Phase I Study of ZD4054 (Zibotentan) and Docetaxel in Patients With Metastatic HRPC
A Phase 1 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 1
- Development phase
- 44
- Enrollment target
NCT00314782 is a Phase 1 study that has completed, run by AstraZeneca. The registered enrollment target is 44 participants.
The verdict
NCT00314782, a Phase 1 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 44 participants
- Enrollment target
Study Summary
Two-part, multi-center study design to establish a maximum tolerated dose (MTD) of ZD4054 in combination with docetaxel and to explore its safety, tolerability, pharmacokinetic (PK) profiles and clinical efficacy in patients with metastatic hormone-refractory prostate cancer (HRPC)
Interventions
- DRUG Placebo
- DRUG Docetaxel
- DRUG ZD4054 (Zibotentan)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 44 participants |
| Start Date | 2006-03 |
| Est. Completion | 2009-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00314782
The ClinicalTrials.gov registry entry for NCT00314782 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 44 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT00314782 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00314782 about?
NCT00314782 is a clinical study titled "Phase I Study of ZD4054 (Zibotentan) and Docetaxel in Patients With Metastatic HRPC". Two-part, multi-center study design to establish a maximum tolerated dose (MTD) of ZD4054 in combination with docetaxel and to explore its safety, tolerability, pharmacokinetic (PK) profiles and clinical efficacy in patients with metastatic hormone-refractory prostate cancer (HRPC)
What is the current status of trial NCT00314782?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 44 participants. The study started on 2006-03. Estimated completion is 2009-03.
What interventions are being tested in trial NCT00314782?
The interventions under investigation include: Placebo (DRUG), Docetaxel (DRUG), ZD4054 (Zibotentan) (DRUG).
Who is sponsoring clinical trial NCT00314782?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.